Notable
BOLD-HTN · MANP · Difficult to Control/ Resistant Hypertension
Primary completion pushed from Jul 1, 2026 to Jul 1, 2027
Also in this update: Trial sites reduced: 29 → 23 locations; Study completion pushed from Sep 1, 2026 to Sep 30, 2027
E-Star BioTech, LLCPhase 2 NCT06343298 Registry history of NCT06343298 on ClinicalTrials.gov (opens the registry)